Am J Transplant, Volume 19, Suppl 3 Archives - Page 31 of 214 - ATC Abstracts

2019 American Transplant Congress
Are We Underestimating The Number Of Paired Kidney Exchange Transplants In The United States? Relationship Insights From The National Kidney Registry
A. Thomas¹, A. Shaffer², D. Segev²
¹Epidemiology, UNC Chapel Hill, Chapel Hill, NC, ²Johns Hopkins University, Baltimore, MD
*Purpose: Despite an overall decline in the number of living donor kidney transplants (LDKTs) since 2005, Kidney Paired Donation (KPD) rates have increased over the…
2019 American Transplant Congress
LCP-Tacrolimus (LCPT; Envarsus XR) Dosing Considerations in De Novo Kidney Transplant Recipients
D. Cibrik¹, P. West-Thielke², S. J. Patel³, D. R. Stevens⁴, U. Meier-Kriesche⁴
¹University of Kansas Medical Center, Kansas City, KS, ²University of Illinois Hospital and Health Sciences System, Chicago, Chicago, IL, ³Veloxis Pharmaceuticals, Cary, NC, ⁴Veloxis Pharmaceuticals Inc., Cary, NC
*Purpose: Different initial dosing strategies were studied in Phase II/Phase III trials evaluating the pharmacokinetics, safety, and efficacy of LCPT in de novo kidney transplantation.…
2019 American Transplant Congress
Opening the Doors of Hope: HIV-Positive Living Kidney Donation
S. Rusch, L. Fieldman, M. Hemmersbach-Miller, C. R. Wolfe
Duke University Medical Center, Durham, NC
*Purpose: Living donation (LD) has been allowed under the HOPE Act since 2013, yet to date there have been no HIV+ LD organ transplants performed…
2019 American Transplant Congress
To Each Their Own: Center-Level Variation in Tailoring Induction Immunosuppression to Kidney Transplant Recipients
S. Bae, A. Massie, J. Garonzik Wang, M. McAdams DeMarco, J. Coresh, D. Segev
Johns Hopkins University, Baltimore, MD
*Purpose: Ideally, induction immunosuppression should be selected in a personalized manner. However, there is little knowledge of what clinical factors are considered in this process…
2019 American Transplant Congress
Lymphotoxin Signaling Regulates T Cell Lymphatic Trafficking
W. Piao¹, L. Li², V. Saxena², Y. Xiong², M. WillsonShirkey², C. Paluskievicz², J. Bromberg³
¹Microbiology and Immunology, U. Maryland, Baltimore, baltimore, MD, ²Surgery, U. Maryland, Baltimore, Baltimore, MD, ³Microbiology and Immunology, U. Maryland, Baltimore, Baltimore, MD
*Purpose: Lymphotoxin (LT) α1β2 is crucial for lymphatic organ development and orchestration of immune responses. LTα1β2 is preferentially expressed by regulatory T cells (Treg) for…
2019 American Transplant Congress
Results from the LIVE-C Free Trial
J. N. Fleming¹, D. DuBay¹, N. L. Jonassaint², R. S. Satoskar³, K. D. Chavin⁴
¹Medical University of South Carolina, Charleston, SC, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³Medstar Georgetown Medical Center, Washington, DC, ⁴University Hospital, Cleveland, OH
*Purpose: Ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) has shown excellent results post-liver transplant. However, due to the poor tolerability of RBV, it is commonly…
2019 American Transplant Congress
Role of Procurement and Reperfusion Biopsy in Kidney Transplant in Evaluating and Predicting Outcomes of Deceased Donor Kidneys
S. Faiz, A. Pai, A. De Golovine, A. Edwards, W. Glass, A. Tchakarov
UT Houston, Houston, TX
*Purpose: Pathologic assessment of donor organs by use of procurement biopsies (PB) provides information regarding organ quality. Most commonly cited reason for organ discard is…
2019 American Transplant Congress
Treatment Modality Affects Outcomes of Recurrent Hepatocellular Carcinoma Following Liver Transplantation: A US Multicenter Analysis of 2786 Patients
P. Tabrizian¹, K. J. Halazun², M. L. Holzner¹, N. Mehta³, F. Y. Yao³, J. Roberts³, J. C. Emond⁴, B. Samstein², R. S. Brown⁴, S. Florman¹, M. E. Schwartz¹, M. M. Doyle⁵, W. C. Chapman⁵, M. Najjar⁴, R. W. Busuttil⁶, V. G. Agopian⁶
¹Transplant, Mount Sinai Medical Center, New York, NY, ²Transplant, Weill Cornell Medicine, New York, NY, ³Transplant, University of California San Francisco, San Francisco, CA, ⁴Transplant, Columbia University Medical Center, New York, NY, ⁵Transplant, Washington University School of Medicine, St Louis, MO, ⁶Transplant, David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Recurrent hepatocellular carcinoma (HCC) following liver transplantation (LT) has a poor prognosis. We evaluated the impact of treatment modalities on post-recurrence survival.*Methods: Adult patients…
2019 American Transplant Congress
Immunomics of Renal Allograft Acute T-Cell Mediated Rejection Biopsies of Tacrolimus- and Belatacept- Treated Patients
M. van der Zwan¹, C. C. Baan¹, R. C. Colvin², R. N. Smith², R. A. White², D. N. Ndishabandi², A. L. Nigg¹, T. P. van den Bosch¹, G. N. de Graav¹, M. C. Clahsen-van Groningen¹, D. A. Hesselink¹
¹Internal Medicine, Division Nephrology and Transplantation, Erasmus MC, Rotterdam, Netherlands, ²Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA
*Purpose: Belatacept-based therapy in kidney transplant recipient has been shown to increase long-term renal allograft and patient survival compared with calcineurin inhibitor based therapy, however…
2019 American Transplant Congress
Recipient Monocytes Activated by Endobronchial Toll-Like Receptor 2 Agonist Prevent Tolerance Induction after Lung Transplantation
S. Tanaka¹, J. M. Gauthier¹, Y. Terada¹, T. Takahashi¹, W. Li¹, R. Higashikubo¹, A. Y. Tong¹, V. Puri¹, A. S. Krupnick², A. E. Gelman¹, D. Kreisel¹
¹Department of Surgery, Washington University in St. Louis, St. Louis, MO, ²Department of Surgery, The University of Virginia, Charlottesville, VA
*Purpose: Extended criteria lung donors are being increasingly utilized, raising the possibility of transplanting lungs with a pre-existing pneumonia; how donor pneumonia alters alloimmune responses,…